Cold Plasma plus Concomitant and Adjuvant Therapies for Cancer Treatment
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Methods and Technologies Development".
Deadline for manuscript submissions: closed (1 December 2023) | Viewed by 1445
Special Issue Editors
Interests: cold plasma; cancer; free radicals; cancer treatments; plasma medicine; autophagy
Interests: cold plasma; cancer; free radicals; cancer treatments; plasma medicine; plasma physics
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cold plasma is a novel, non-thermal technology that generates reactive oxygen and nitrogen species, as well as other biologically active molecules, which have been shown to induce cancer cell death while sparing normal cells. Although cold plasma has shown promising results as an anti-cancer therapy, its efficacy as a standalone treatment is limited. Therefore, this Special Issue explores the use of cold plasma in combination with concomitant and adjuvant therapies for cancer treatment.
Concomitant therapies refer to the use of cold plasma alongside conventional cancer treatments, such as chemotherapy and radiation therapy. Studies have demonstrated that using cold plasma alongside chemotherapy or radiation therapy enhances their efficacy by sensitizing cancer cells to the treatment, thereby increasing cell death. On the other hand, adjuvant therapies refer to the use of cold plasma alongside complementary therapies, such as immunotherapy and photodynamic therapy, which have shown promising results in cancer treatment. These combinations can also enhance the immune system's response to cancer and improve the effectiveness of the therapy.
The evidence from the latest research demonstrate the potential of cold plasma to act synergistically with concomitant and adjuvant therapies, which could lead to more effective and less toxic cancer treatments. However, further research is needed to optimize the use of cold plasma in combination with other therapies and to evaluate its potential as a standalone treatment for cancer. The main focus of this Issue aims to publish papers on different kinds of cancers treated with cold plasma with/without a combination of another agent. Overall, this Special Issue highlights the potential of cold plasma as an effective and complementary therapy for cancer treatment.
Dr. Manish Adhikari
Prof. Dr. Michael Keidar
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cold plasma
- cancer
- free radicals
- cancer treatments
- plasma medicine
